Aptus Endosystems Obtains $25,000,000 New Financing Round

  • Feed Type
  • Date
  • Company Name
    Aptus Endosystems
  • Mailing Address
    777 N. Pastoria Avenue Sunnyvale, CA 94085
  • Company Description
    Aptus Endosystems is a privately held, well-funded, emerging medical device company that is engaged in the development of next generation minimally invasive endograft devices, delivery systems and fixation technology for the treatment of Abdominal Aortic Aneurysm – the 13th leading cause of death in the United States and the 10th leading cause of death in men over the age of 55.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds from the financing will be used to expand commercialization of the HeliFX Aortic Securement System in the United States and Europe, where the company has already obtained US Food and Drug Administration (FDA) clearance and CE Mark, respectively. In addition, Aptus will develop further HeliFX product offerings to fulfill unmet needs in the treatment of aortic aneurysms and thus increase the patient population who could benefit from HeliFX. The company also plans to execute a US clinical trial of the Fortevo AAA Endograft System in support of filing for Premarket Approval with the FDA. Lastly, Aptus will expand utilization of the Fortevo system in key European centers, where it already possesses the CE Mark.
  • M&A Terms
  • Venture Investor
    Synergy Life Science Partners
  • Venture Investor
    U.S. Venture Partners
  • Venture Investor
    Longitude Capital Management

Trending on Xconomy